Jupiter Neurosciences Files 8-K: Material Agreement Announced

TL;DR

JUPITER NEUROSCIENCES (JBNA) filed an 8-K for a material definitive agreement on 12/15/24. Details TBD.

AI Summary

Jupiter Neurosciences, Inc. announced on December 15, 2024, that it entered into a Material Definitive Agreement. The company also filed financial statements and exhibits as part of this report. The filing does not specify the nature of the agreement or any associated financial figures.

Why It Matters

This 8-K filing indicates a significant development for Jupiter Neurosciences, Inc., potentially involving a new partnership, acquisition, or financing, which could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement and its financial implications introduces uncertainty.

Key Players & Entities

• JUPITER NEUROSCIENCES, INC. (company) — Registrant
• December 15, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-41265 (identifier) — Commission File Number
• 47-4828381 (identifier) — IRS Employer Identification No.
• 1001 North US HWY 1 , Suite 504 Jupiter , FL 33477 (address) — Address of Principal Executive Offices
• (561) 406-6154 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $2,300,000 — Dominant Treasure a one-time payment of $2,300,000. In addition, if Dominant Treasure is i

Filing Documents

• form8-k.htm (8-K) — 40KB
• ex10-1.htm (EX-10.1) — 9KB
• ex10-1_001.jpg (GRAPHIC) — 58KB
• ex10-1_002.jpg (GRAPHIC) — 291KB
• ex10-1_003.jpg (GRAPHIC) — 219KB
• ex10-1_004.jpg (GRAPHIC) — 229KB
• ex10-1_005.jpg (GRAPHIC) — 305KB
• ex10-1_006.jpg (GRAPHIC) — 269KB
• ex10-1_007.jpg (GRAPHIC) — 242KB
• ex10-1_008.jpg (GRAPHIC) — 99KB
• 0001493152-24-050801.txt ( ) — 2581KB
• juns-20241215.xsd (EX-101.SCH) — 3KB
• juns-20241215_lab.xml (EX-101.LAB) — 33KB
• juns-20241215_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2024 JUPITER NEUROSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-41265 47-4828381 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1001 North US HWY 1 , Suite 504 Jupiter , FL 33477 (Address of Principal Executive Offices) (Zip Code) (561) 406-6154 (Registrant's Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock JUNS Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01 Entry into a Material Definitive Agreement. On December 15, 2024, Jupiter Neurosciences, Inc. (the "Company") entered into a Strategic Services Agreement (the "Dominant Treasure Agreement") with Dominant Treasure Health Company Limited ("Dominant Treasure"). Pursuant to the terms of the Dominant Treasure Agreement, Dominant Treasure agreed to provide certain services to the Company to assist the Company in accelerating the Company's desire to get its products developed and distributed in the Southeast Asian market. In exchange for Dominant Treasure's services pursuant to the Dominant Treasure Agreement, the Company agreed to pay Dominant Treasure a one-time payment of $2,300,000. In addition, if Dominant Treasure is involved in generating negotiations and conclusion of a distribution agreement for the Company in the countries of China (including Hong Kong), Singapore and Malaysia, the Company will pay Dominant Treasure a success fee of 5% of any upfront and/or milestone payments to be received by the Company. If such agreement will include a royalty payment to the Company, Dominant Treasure will receive 5% of such royalty payment. The Dominant Treasure Agreement has a term of 36 months and may be terminated at any time upon mutual agreement of the parties. The foregoing summary of the Dominant Treasure Agreement is qualified in its entirety by reference to the full text of the Dominant Treasure Agreement, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. Item 9.01 Financial Statement and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Strategic Services Agreement, dated December 15, 2024, by and between Jupiter Neurosciences, Inc. and Dominant Treasure Health Company Limited. 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded with the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. JUPITER NEUROSCIENCES, INC. Dated: December 19, 2024 By: /s/ Christer Rosn Christer Rosn Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR